MoonLake Immunotherapeutics

Report azionario NasdaqCM:MLTX

Capitalizzazione di mercato: US$1.3b

MoonLake Immunotherapeutics Gestione

Criteri Gestione verificati 3/4

MoonLake Immunotherapeutics Il CEO è Jorge da Silva, nominato in Jul2021, e ha un mandato di 4.83 anni. la retribuzione annua totale è $ 4.94M, composta da 15.4% di stipendio e 84.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.01% delle azioni della società, per un valore di $ 54.02M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.9 anni e 4.1 anni.

Informazioni chiave

Jorge da Silva

Amministratore delegato

US$4.9m

Compenso totale

Percentuale dello stipendio del CEO15.42%
Mandato del CEO4.8yrs
Proprietà del CEO4.0%
Durata media del management2.9yrs
Durata media del Consiglio di amministrazione4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Jul 26

Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jun 03

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest

Summary MoonLake Immunotherapeutics completed enrollment in the two-phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights the significant buyout potential of the company and validates its late-stage pipeline value. MLTX's strong cash position funds operations into 2028, but risks remain around clinical trial outcomes and competitive benchmarks, especially versus SKYRIZI in PsA. Read the full article on Seeking Alpha
Articolo di analisi • Apr 09

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 08

MoonLake Immunotherapeutics: A Buy At Dips

Summary MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed results from the ARGO study, sonelokimab demonstrated superior efficacy against Humira and Secukinumab, indicating strong potential for future success. Institutional sell-offs in late 2023 caused a drastic stock decline, but MLTX remains financially stable with a cash runway extending into 2027. With promising catalysts in 2025 and potential market opportunities worth billions, MLTX is a buy on dips for risk-tolerant investors. Read the full article on Seeking Alpha
Articolo di analisi • Jan 20

Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?

Key Insights Using the 2 Stage Free Cash Flow to Equity, MoonLake Immunotherapeutics fair value estimate is US$72.37...
Articolo di analisi • Dec 16

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 13

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold

Summary MoonLake Immunotherapeutics' stock has been volatile but is currently back to its previous year's level, reflecting mixed performance in a bullish biotech market. SLK, MoonLake's key asset, shows promising Phase 2b results in HS, PsA, and psoriasis, with Phase 3 trials ongoing and new indications being explored. Financially, MLTX has a $3bn market cap and $520mn cash, ensuring a runway of 10-12 quarters despite significant R&D expenses. The primary risk is the lack of near-term catalysts, with significant data expected only by mid-2025, making it a hold rather than a buy. Read the full article on Seeking Alpha
Articolo di analisi • Aug 27

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jul 18

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

Summary MoonLake Immunotherapeutics launched VELA-1 and VELA-2 as two studies using sonelokimab for the treatment of patients with Hidradenitis Suppurativa; Topline 16-week primary endpoint expected end of 2026. The global hidradenitis suppurativa market is expected to reach $1 billion by 2029. The initiation of the IZAR program, using sonelokimab for patients with Psoriatic Arthritis, is expected to launch in Q4 of 2024; Primary endpoint data is expected at the end of 2026. There is potential to establish a competitive advantage by using Nanobody technology, which incorporates smaller molecules along with drugs developed to target both cytokines IL-17A and IL-17F. Read the full article on Seeking Alpha
Articolo di analisi • May 14

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Feb 26

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Summary MoonLake Immunotherapeutics has exclusively licensed nanobody technology to develop treatments for inflammatory diseases. The company is focusing on psoriasis and hidradenitis suppurativa, targeting interleukins 17A and 17F as the main culprits for excessive inflammation. MoonLake has completed phase 2 clinical trials and is entering phase 3, showing promising results so far, but there are still development risks and outstanding financial burdens. The value gap exists, which is positive, but with the development risks of a novel technology, we aren't sure what sort of margin of safety can be expected. Read the full article on Seeking Alpha
Articolo di analisi • Jan 29

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 16

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, MoonLake...
Seeking Alpha • Jul 26

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

MoonLake Immunotherapeutics (NASDAQ:MLTX) on Tuesday said it had signed a services agreement with contract development and manufacturing organization Vetter Pharma International GmbH. As per the deal, Vetter will be responsible for fill and finish services. Vetter will oversee the the aseptic filling of syringes with MLTX's investigational nanobody sonelokimab. Vetter will also be responsible for the subsequent assembly into an autoinjector combination device and packaging. MLTX stock -1.8% to $6.93 in morning trading.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jorge da Silva rispetto agli utili di MoonLake Immunotherapeutics?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$257m

Dec 31 2025US$5mUS$762k

-US$227m

Sep 30 2025n/an/a

-US$210m

Jun 30 2025n/an/a

-US$176m

Mar 31 2025n/an/a

-US$145m

Dec 31 2024US$1mUS$698k

-US$119m

Sep 30 2024n/an/a

-US$81m

Jun 30 2024n/an/a

-US$55m

Mar 31 2024n/an/a

-US$41m

Dec 31 2023US$1mUS$586k

-US$36m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$4mUS$460k

-US$50m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$54m

Dec 31 2021US$5mUS$230k

-US$64m

Compensazione vs Mercato: La retribuzione totale di Jorge ($USD 4.94M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 5.45M ).

Compensazione vs guadagni: La retribuzione di Jorge è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Jorge da Silva (48 yo)

4.8yrs
Mandato
US$4,943,209
Compensazione

Dr. Jorge Santos da Silva, Ph D., is a Co-Founder of MoonLake Immunotherapeutics (Alternate name MoonLake Immunotherapeutics AG) and has served as the Chief Executive Officer since April 2022 and serves as...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Jorge da Silva
Co-Founder4.8yrsUS$4.94m4.01%
$ 54.0m
Kristian Reich
Co-Founder & Chief Scientific Officer4.1yrsUS$4.80m4.13%
$ 55.6m
Matthias Bodenstedt
Chief Financial Officer4.1yrsUS$4.69m1.61%
$ 21.7m
Oliver Daltrop
Chief Technical Officerno dataNessun datoNessun dato
Carla Bretes
Director of Investor Relations & External Communications2.3yrsNessun datoNessun dato
Nicolas Mosimann
General Counsel3.4yrsNessun datoNessun dato
Joana Cortez
Associate Vice-President of Legal & Compliance2.3yrsNessun datoNessun dato
Tino Anthamatten
Vice President of Marketing2.3yrsNessun datoNessun dato
Luciana Marques
Associate Vice-President of HR2.3yrsNessun datoNessun dato
Nuala Brennan
Chief Clinical Development Officer4.7yrsNessun datoNessun dato
Roman Akbar-Haase
Chief of Staff to the Executive Board2.3yrsNessun datoNessun dato
Wulf Boecher
Chief Medical Officerno dataNessun datoNessun dato
2.9yrs
Durata media
48yo
Età media

Gestione esperta: Il team dirigenziale di MLTX è considerato esperto (durata media dell'incarico 2.9 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Jorge da Silva
Co-Founder4.1yrsUS$4.94m4.01%
$ 54.0m
Catherine Moukheibir
Independent Director4.1yrsUS$286.85k0%
$ 0
Andrew Phillips
Independent Director4.1yrsUS$280.35k0%
$ 0
Ramnik Xavier
Independent Director4.1yrsUS$299.35k0%
$ 0
Spike Loy
Lead Independent Director4.1yrsUS$276.85k0%
$ 0
4.1yrs
Durata media
53yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MLTX sono considerati esperti (durata media dell'incarico 4.1 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 15:43
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

MoonLake Immunotherapeutics è coperta da 16 analisti. 13 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Julian HarrisonBTIG
Prakhar AgrawalCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc